Lorukafusp alfa | MedChemExpress (MCE)
Lorukafusp alfa (14.18 mAb; hu14.18-IL2) is an immunocytokine consisting of the humanized 14.18 anti-GD2 mAb linked to IL210. Lorukafusp alfa has activity mediated by activation of antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity via the binding of hu14.18-IL2 to GD2 on the tumor cell surface, followed by binding to Fc receptors on effector cells along with activation of NK and T cells via IL2 receptor binding. Lorukafusp alfa has anti-tumor activity[1].
Trivial name | Lorukafusp alfa |
Catalog Number | HY-P990076 |
Alternative Name(s) | 14.18 mAb; hu14.18-IL2; EMD 273063 |
Research Area | Cancer |
CAS# | 2131168-99-3 |
Purity | ≥98.00% |
SMILES | [Lorukafusp alfa] |
Size | 1 mg |
Supplier Page | https://www.medchemexpress.com/lorukafusp-alfa.html |